LEF1: A Protein Involved in Cell-cell Adhesion and Disease (G51176)

Target Name: LEF1

NCBI ID: G51176

LEF1

LEF1: A Protein Involved in Cell-cell Adhesion and Disease

LEF1 (Tcf1alpha), a protein that belongs to the TCF1 family, is a key regulator of cell-cell adhesion and has been implicated in various diseases, including cancer. The TCF1 family consists of four subunits: Tcf1a, Tcf1b, Tcf1c, and Tcf1d. LEF1, also known as Tcf1alpha, is the most well-studied subunit and is involved in many cellular processes, including cell adhesion, migration, and invasion.

LEF1 is a 21-kDa transmembrane protein that is expressed in most tissues of the body. It plays a crucial role in cell-cell adhesion by interacting with several adhesion molecules, including cadherins, E-cadherins, and integrins. LEF1 has been shown to regulate the assembly and disassembly of these adhesion molecules, thereby controlling the movement and behavior of cells.

In addition to its role in cell adhesion, LEF1 is also involved in various signaling pathways that regulate cell behavior, including the cell cycle, apoptosis, and inflammation. LEF1 has been shown to interact with several signaling molecules, including TGF-beta, NF-kappa-B, and AP-1. These interactions allow LEF1 to regulate cell proliferation, survival, and differentiation, as well as the inflammatory response.

LEF1 has also been implicated in various diseases, including cancer. For example, LEF1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancers. This increase in LEF1 expression has been associated with cancer cell survival and the development of cancer-initiating events.

In addition to its role in cancer, LEF1 is also involved in the development and progression of other diseases, including neurodegenerative disorders and autoimmune diseases. For example, LEF1 has been shown to be involved in the development of neurodegenerative disorders, such as Alzheimer's disease, by regulating the clearance of neurotransmitters and modulating the activity of neurotransmitter receptors. It has also been implicated in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, by regulating the activity of immune cells and modulating the immune response.

In conclusion, LEF1 is a highly conserved protein that plays a crucial role in various cellular processes, including cell adhesion and signaling pathways. Its involvement in various diseases, including cancer and neurodegenerative disorders, makes it an attractive drug target and a potential biomarker for diagnostic purposes. Further research is needed to fully understand the role of LEF1 in these diseases and to develop effective therapies that target this protein.

Protein Name: Lymphoid Enhancer Binding Factor 1

Functions: Transcription factor that binds DNA in a sequence-specific manner (PubMed:2010090). Participates in the Wnt signaling pathway (By similarity). Activates transcription of target genes in the presence of CTNNB1 and EP300 (By similarity). PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1 (By similarity). TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1 (PubMed:11266540). Regulates T-cell receptor alpha enhancer function (PubMed:19653274). Required for IL17A expressing gamma-delta T-cell maturation and development, via binding to regulator loci of BLK to modulate expression (By similarity). May play a role in hair cell differentiation and follicle morphogenesis (By similarity)

The "LEF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LEF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets